Stroke is a major cause of morbidity and mortality in Asia, and its pattern is changing. The incidence of haemorrhagic stroke is declining while the incidence of ischaemic stroke caused by large artery atherothromboembolism is increasing secondary to an increase in the prevalence of hypercholesterolaemia. The Working Group on Stroke and Lipids Management in Asia Consensus Panel assembled leading experts from the region to reach a consensus on how to address this challenge. The group discussed the observational epidemiology of the relationship between cholesterol and risk of stroke, the clinical trial evidence base for cholesterol-lowering for stroke prevention, and issues specific to stroke and lipid management for Asian doctors and patients. Stroke guidelines from many of the Asian countries have recently recommended consideration of statins for recurrent stroke prevention in patients with previous ischaemic stroke or transient ischaemic attack. However, because these recommendations have yet to be Judith Frayne has received honoraria from Boehringer-Ingelheim GmbH, Eli Lilly and Company, Pfizer Inc., and sanofi-aventis. She has also served on advisory boards for Eli Lilly and Company and Pfizer Inc. Graeme J. Hankey has received honoraria for presentations at sponsored scientific symposia and consulting on advisory boards for Pfizer Inc.
Introduction
Stroke is a major cause of death and disability in Asia and it threatens to impose a greater burden in the future (1) (2) (3) (4) . Although stroke mortality rates have declined since the 1970s, when they were higher than any other disease, the rate of decline is decelerating (3, 5) . This has been attributed to an increase in the incidence of ischaemic stroke caused by both extracranial and intracranial large-artery atherothromboembolism, which, in turn, has been attributed to an increase in the prevalence of hypercholesterolaemia associated with increasing dietary intake of saturated fats, physical inactivity, obesity, and diabetes (6) (7) (8) 9) . Indeed, the population-attributable risk of ischaemic stroke due to nonoptimal blood cholesterol concentration has been estimated to be as high as 45% in Asian-Pacific countries (10) .
The purpose of this review is to examine the evidence for hypercholesterolaemia as a causal and treatable risk factor for stroke in Asian populations, and to reach a consensus among leading Asian stroke physicians as to how hypercholesterolaemia may be optimally managed to minimise the looming epidemic of stroke in Asia.
Methods
The Working Group on Stroke and Lipids Management in Asia Consensus Panel was cochaired by Professor Graeme Hankey and Professor Ka Sing Lawrence Wong, and comprised a total of 15 members representing 11 East Asian and Western Pacific countries and regions: Australia, China, Hong Kong, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand ( Table 1 ). The panel met in March 2008 in Siem Reap, Cambodia, and in November 2008 in Beijing, China (both meetings were supported by Pfizer Inc.). The purpose of the meetings was this review.
Results
Hypercholesterolaemia as a risk factor for stroke Meta-analyses of observational studies do not show an overall association between plasma cholesterol and all types of fatal stroke (11, 12) . However, they do show a weak positive association between increasing plasma cholesterol and increasing ischaemic and total stroke mortality among individuals in early middle age (40-59 years) and with below-average blood pressure (systolic blood pressure o145 mmHg) (11, 12) . They also show a weak negative association between decreasing plasma cholesterol and increasing haemorrhagic and total stroke mortality among individuals in older age (70-89 years) and with higher blood pressure (systolic blood pressure 4145 mmHg) (11, 12) . A large, prospective, cohort study of 787 442 Korean civil servants aged 30-64 years showed that high alcohol consumption might underlie the association between low blood cholesterol and increased risk of haemorrhagic stroke (13, 14) .
Intracranial atherosclerosis is the main stroke subtype in some parts of Asia (15) . Hyperlipidaemia, especially a high concentration of low-density lipoprotein cholesterol (LDL-C), has been implicated as one of the risk factors for intracranial atherosclerosis in a population-based study and a stroke cohort (16, 17) .
Randomised-controlled trials of statins for stroke prevention

All stroke
A recent meta-analysis of the 24 published randomised trials comparing statins with control among 165 792 individuals found that random assignment to a statin was associated with a reduction in the incidence of all strokes (first-ever and recurrent, ischaemic and haemorrhagic) by about one-fifth [relative risk (RR) 0Á82, 95% CI: 0Á77-0Á87] compared with control ( Fig. 1) (18) . There was no evidence of heterogeneity across the trials. Each 1 mmol/l reduction in the LDL-C concentration was associated with a reduction in the RR for stroke by one-fifth (RR 0Á79, 95% CI: 0Á67-0Á94) (18) .
A possible explanation for the discrepancy between the observational epidemiology and the results of randomised trials is that increasing blood cholesterol concentration may be associated causally with an increasing risk of ischaemic stroke due to large-artery atherothromboembolism (19) but not to haemorrhagic stroke or other causes of ischaemic stroke, such as arterial dissection and cardiac embolism (e.g., valvular heart disease).
Recurrent stroke
Among the four trials that examined the effects of statins in patients with a previous stroke, random assignment to a statin was associated with a significant reduction in the RR of recurrent stroke (RR 0Á84, 95% CI: 0Á71-0Á99) and of major cardiovascular events (RR 0Á80, 95% CI: 0Á69-0Á92) compared with control (18) .
Haemorrhagic stroke
Among the 10 trials of statins in 83 205 patients, which subclassified stroke outcome events into ischaemic and haemorrhagic stroke, random allocation to a statin was not associated with any overall increase in the incidence of haemorrhagic stroke (RR 1Á03, 95% CI: 0Á75-1Á41) (18) . However, a post hoc subgroup analysis revealed differences in the direction of the treatment effect according to whether the patient had a past history of stroke or not. Among the primary prevention trials in patients without a past history of stroke, random assignment to a statin was associated with a trend towards a reduction in haemorrhagic stroke (RR 0Á81, 95% CI: 0Á60-1Á08), whereas among the two secondary prevention trials in patients with a past history of stroke, no matter what type, random assignment to a statin was associated with an increase in haemorrhagic stroke (RR 1Á73, 95% CI: 1Á19-2Á50) (18, 20, 21) . Multivariate analysis of the predictors of haemorrhagic stroke among patients randomised in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial (21) raised the hypothesis that increasing age, male gender, haemorrhagic stroke as a qualifying event in the trial, treatment with atorvastatin, and stage II hypertension at last visit before the haemorrhagic stroke were associated with an increased risk of haemorrhagic stroke (22) . Others have suggested that low cholesterol concentrations may predispose to MRI evidence of cerebral microbleeds (23, 24) but this remains to be confirmed.
Asians
There have been three cholesterol-lowering clinical trials in Asian patients in which stroke was recorded as an outcome (secondary) event.
The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) trial randomised 7832 Japanese patients to pravastatin 10-20 mg/day plus diet or diet alone (25) . Random assignment to diet plus pravastatin was associated with a significant reduction in the primary outcome of first occurrence of coronary heart disease (HR 0Á67, 95% CI: 0Á49-0Á91), a nonsignificant reduction in total stroke (HR 0Á83, 95% CI: 0Á57-1Á21), a nonsignificant reduc- tion in cerebral infarction (HR 0Á76, 95% CI: 0Á49-1Á18), and a nonsignificant increase in intracranial haemorrhage (HR 1Á18, 95% CI: 0Á58-2Á42) compared with diet alone (25) . The Japan EPA Lipid Intervention Study (JELIS) randomly assigned 18 645 hypercholesterolaemic Japanese patients to statin therapy (pravastatin 10-20 mg or simvastatin 5-10 mg daily) or the addition of eicosapentaenoic acid (EPA) 1800 mg/ day to statin therapy (26) . After 5 years of follow-up, combination therapy was associated with a reduction in major coronary events (RR 0Á81, 95% CI: 0Á69-0Á95) but no reduction in firstever stroke (HR 1Á08, 95% CI: 0Á95-1Á22) (26, 27) . Among the 942 patients who had a history of a previous stroke, EPA plus statin therapy was associated with a significant reduction in the RR of recurrent stroke by about one-fifth (HR 0Á80, 95% CI: 0Á64-0Á997) (27) .
The Regression of Cerebral Artery Stenosis (ROCAS) study was started in the mid 1990s in China and Hong Kong. Asymptomatic patients with vascular risk factors were screened for middle cerebral artery (MCA) stenosis (28) . After confirmation by an MR angiogram, patients were randomised to either simvastatin 20 mg daily or placebo and followed for 2 years. The study failed to show any benefit of simvastatin in regressing the MCA stenosis, the primary outcome, but the effects on clinical events were more promising. There tended to be less death, stroke/TIA, or ischaemic heart disease in the statin group than in the placebo group (4Á4% vs. 11Á4%, P 5 0Á052). Although the sample size was small (N 5 227), the results were consistent with the findings in the coronary circulation that statins appeared to be better in reducing clinical outcomes than regressing atheroma. Furthermore, in a post hoc analysis of those patients with very severe white matter changes in addition to MCA stenosis, low-dose statins appeared to retard the growth of the white matter changes (29) .
Issues for Asian physicians and their patients
The Consensus Panel identified several issues that concern Asian physicians in their approach to the management of hypercholesterolaemia for stroke prevention.
Limited evidence for statins in Asians
The evidence from randomised trials of statins in Asian patients is limited to the MEGA and the ROCAS studies (25, 28) ; the JELIS trial is a trial of EPA therapy (26, 27) . Nevertheless, the results are consistent with those of trials in non-Asian patients: statin treatment was associated with about a one-fifth reduction in the risk of stroke compared with placebo, suggesting that the observed effect of statins in non-Asians may be generalisable to Asians.
Further verification of this hypothesis may be forthcoming from the ongoing Japan Statin Treatment Against Recurrent Stroke trial, which is evaluating the prolonged effect over 5Á5 years of pravastatin 10 mg compared with active control on recurrent stroke in 3000 Japanese patients with previous noncardioembolic ischaemic stroke (30) .
Difficulty extrapolating the evidence to possibly different phenotypes (Asians)
Stroke subtypes and causes of stroke The proportions of different pathological and aetiological subtypes of stroke differ between Asians and Caucasians; haemorrhagic stroke, small vessel disease, and intracranial atherosclerosis are more common among Asians, whereas extracranial atherosclerosis is more common among Caucasians. Although there are emerging trends towards increasing extracranial large-artery atherosclerotic ischaemic stroke among Asians (as Asian societies become more westernised and urbanised), it is possible that cholesterol and cholesterollowering may have different effects on the different subtypes of stroke (15, (31) (32) (33) (34) (35) .
Possible different dose response to statin therapy A review of statin studies conducted in Asia (36) suggested that lower doses of statins achieved lipid changes and outcomes comparable with those observed at higher doses in Caucasians. If validated, the potential mechanisms for such a heightened response could be ascribed to genetic differences in statin metabolism (36) .
Asian physicians have also expressed concern that statins may produce a higher rate of side effects, such as myalgia, malaise, and liver function abnormalities, in Asians compared with Caucasians, but evidence to date shows no increased rates of adverse events in Asian patients taking statins (36) .
Costs
With limited financial resources, there is understandable reluctance among Asian patients and clinicians to add a relatively expensive statin drug to a regimen that already includes an antihypertensive and antiplatelet drug in many Asian stroke patients (37) .
Cultural issues
There is also a cultural reluctance to add Western medicine to traditional ways of treatment, such as herbal medicine or acupuncture (38) . There is general acceptance that Western medicine may be useful for 'curing' acute conditions, but there is cultural resistance to taking allopathic medicine for longterm disease prevention because traditional medicines are considered safer and more 'restorative'.
Recommendations for clinicians
Stroke guidelines from many of the Asian countries have recommended consideration of statins for recurrent stroke prevention in patients with previous ischaemic stroke or transient ischaemic attack (Table 2 ). Such statements are part of the stroke guidelines from Australia, China, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand (39) (40) (41) (42) (43) (44) (45) (46) (47) . The recommendation of an LDL-C target o100 mg/dl is widespread, and some guidelines, such as those from the Philippines, Thailand, and China, recommend more aggressive targeting of o70 or o80 mg/dl for very highrisk patients, similar to the US National Cholesterol Education Project Adult Treatment Panel III guidelines (48) . These guidelines also contain cautions regarding the use of statins in patients with haemorrhagic stroke. The guidelines from Japan, Malaysia, and Singapore are presently being revised (43, 45, 49) .
Recommendations for researchers
Further trials of statins in Asian patients, particularly those with intracranial stenosis, are warranted to refine the overall estimates of benefit, and identify which patients are most likely to benefit from statins. Future global trials of statins in stroke should therefore include Asian sites and patients.
